-
Notable Insider Buys In The Past Week: General Electric, Symantec And More
Monday, August 19, 2019 - 4:22pm | 708Read More...Insider buying can be an encouraging signal for potential investors. Insider purchasing was seen at companies favored by Carl Icahn and George Soros last week. The CEO of an industrial giant put his money where his mouth is as well. Conventional wisdom says that insiders and 10% owners really...
-
Barron's On: Pharma's Big Hope
Sunday, March 3, 2019 - 10:47am | 465Read More...This weekend's Barron's cover story looks at why pharmaceutical giants are making big bets on gene therapy. See which companies already have been snapped up and which ones may be the next targets. Other notable articles offer a look at the implications of the tax law and a retirement guide...
-
Sarepta Therapeutics Volatile After Traders React To Exondys 51 Adverse Events
Friday, September 29, 2017 - 12:29pm | 152Read More...Sarepta Therapeutics (NASDAQ: SRPT) shares are trading lower by $1.50 at $45.59 in Friday's session. Off the open, the issue made a test of Thursday's high ($47.78), but only reached $47.72. Just after 10 a.m. EST, investors reacted to a FDA report of 11 serious cases of adverse effects,...
-
Barron's Picks And Pans: Bank Stocks, O'Reilly Automotive, Sarepta And More
Sunday, April 23, 2017 - 12:11pm | 642Read More...This weekend's Barron's takes a look at the unusual value stock picks at one off the radar hedge fund. Other featured articles offer the prospects for top banks now that they have pulled back and a biotech company that is a potential takeover target. The outlook for an auto parts...
-
2 Opposing Views On The Future Of Sarepta
Thursday, December 22, 2016 - 12:47pm | 541Read More...Sarepta Therapeutics Inc (NASDAQ: SRPT), a biopharmaceutical company that focuses on the treatment of rare diseases, such as Duchenne Muscular Dystrophy (DMD), has become one of the most debated stocks of 2016. After bottoming at $8 per share in early 2016 the stock soared as high as $63.73...
-
Patent Trial And Appeal Board Hands Sarepta Another Big Win
Wednesday, September 21, 2016 - 10:50am | 358Read More...Sarepta Therapeutics Inc (NASDAQ: SRPT) announced Tuesday that the Patent Trial and Appeal Board issued two favorable decisions for Sarepta which refused BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)'s claims. In a report, Brian Skorney of Baird suggested the PTAB's ruling implies Sarepta...
-
Sarepta Prices Newly-Approved DMD Drug, Cowen Upgrades Stock To Outperform
Tuesday, September 20, 2016 - 10:24am | 300Read More...Sarepta Therapeutics Inc (NASDAQ: SRPT) hosted a conference call Tuesday to discuss its newly approved drug, Exondys 51 (eteplirsen) injection, which happens to be the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Sarepta said Exondys 51 will be available in a...
-
Why Did Sarepta Therapeutics Plunge 20%?
Thursday, June 2, 2016 - 10:26am | 347Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) plunged more than 20 percent on Thursday after reports surfaced that the U.S. Food and Drug Administration may pressure the company to provide its Duchenne muscular dystrophy patients with at-cost access to its eteplirsen therapy on a "...
-
Sarepta Therapeutics Surges 20% On No News
Friday, May 20, 2016 - 6:51am | 339Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) were trading higher by 20 percent at one point early Friday morning on no confirmed news reports. Sarepta's investor relations website showed no new updates. Meanwhile, Twitter users were sharing various theories to explain the unexpected surge in...
-
The Street's Feuerstein Breaks Down Sarepta's 40% Plunge
Thursday, April 21, 2016 - 9:51am | 338Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) plunged more than 40 percent on Thursday after the U.S. Food and Drug Administration released briefing documents which consisted of an updated clinical review of the company's Duchenne muscular dystrophy drug, eteplirsen. According to The...
-
Barron's Picks And Pans: Ford, Intel, Sealed Air And More
Sunday, April 17, 2016 - 5:47pm | 670Read More...Featured stories this weekend in Barron's ponder the prospects for a Detroit automaker, a semiconductor giant and the inventor of Bubble Wrap. This issue also has a look at a jet propulsion company and a pair of small cap banks. Other articles discuss the state of the U.S. auto industry, the top...
-
Sarepta Therapeutics Dropped 10% Following FDA News
Monday, February 8, 2016 - 1:01pm | 209Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) plunged more than 10 percent on Monday and hit a new 52-week low of $10.60 after the company received a notification from the U.S. Food and Drug Administration. The FDA told Sarepta Therapeutics that it requires additional time to complete its...
-
Forbes: There Is 'A Bit' Of Hope For Sarepta Therapeutics
Friday, January 22, 2016 - 3:38pm | 209Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) were trading higher by more than 3 percent on Friday, but have lost more than 60 percent after the FDA released a briefing document related to the company's eteplirsen. Related Link: Sarepta Crashes 50% Amid Efficacy Concern Related To Eteplirsen...
-
Barron's Recap: 16 All-Star Women Financial Advisors
Sunday, November 22, 2015 - 10:39am | 977Read More...The cover story in this weekend's Barron's is a look at the biggest battle in biotechnology. This issue also includes a special report on 16 all-star women advisors and a look at companies that could double earnings. The prospects for Whirlpool, Procter & Gamble, Express...
-
Markets Continue To Rally As The Dow Closes Above 17,000
Tuesday, October 28, 2014 - 3:44pm | 1552Read More...U.S. stocks continued to charge forward as the Dow closed above the 17,000 mark as consumer confidence rose more than expected in October. The Federal Reserve gathered Tuesday and will release a statement on Wednesday at 2:00 p.m. ET. It is not a foregone conclusion that the Federal Reserve...
